Table 4C.
Univariable and multivariable analysis of predictors of mortality in the NHL patients.
| NHL | ||||||||
|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | |||||||
| p value | HR | 95% CI | p value | HR | 95% CI | |||
| Lower | Upper | Lower | Upper | |||||
| Sex | ||||||||
| Female | - | - | - | - | ||||
| Male | 0.536 | 1.170 | 0.711 | 1.926 | ||||
| Age | 0.002 | 1.031 | 1.011 | 1.052 | <0.001 | 1.045 | 1.023 | 1.067 |
| Status malignancy at COVID-19 diagnosis | ||||||||
| Controlled disease | - | - | - | - | - | - | - | - |
| Stable disease | 0.912 | 1.056 | 0.406 | 2.742 | 0.940 | 0.964 | 0.368 | 2.524 |
| Active disease | 0.017 | 1.885 | 1.121 | 3.170 | 0.001 | 2.363 | 1.391 | 4.016 |
| Malignancy | ||||||||
| Chronic lymphoid leukemia | ||||||||
| Non-Hodgkin lymphoma | ||||||||
| COVID-19 infection | ||||||||
| Asymtomatic | - | - | - | - | - | - | - | - |
| Mild | 0.589 | 1.311 | 0.491 | 3.499 | 0.352 | 1.623 | 0.585 | 4.503 |
| Severe | 0.269 | 1.559 | 0.710 | 3.424 | 0.111 | 1.977 | 0.855 | 4.572 |
| Critical | 0.002 | 3.817 | 1.666 | 8.744 | <0.001 | 5.969 | 2.450 | 14.543 |
| Chronic cardiopathy | 0.106 | 1.522 | 0.915 | 2.534 | ||||
| Chronic pulmonary disease | 0.596 | 1.175 | 0.648 | 2.131 | ||||
| Diabetes mellitus | 0.158 | 1.554 | 0.843 | 2.862 | ||||
| Liver disease | 0.332 | 0.375 | 0.052 | 2.721 | ||||
| Obesity | 0.477 | 0.599 | 0.146 | 2.453 | ||||
| Renal impairment | 0.207 | 1.815 | 0.719 | 4.584 | ||||
| Smoking history | 0.175 | 1.676 | 0.795 | 3.530 | ||||
| Neutrophils | ||||||||
| ≤ 500 | - | - | - | - | ||||
| 501 - 999 | 0.374 | 1.761 | 0.505 | 6.135 | ||||
| ≥ 1000 | 0.560 | 0.760 | 0.301 | 1.916 | ||||
| Lymphocytes | ||||||||
| ≤ 200 | – | – | – | – | ||||
| 201 - 499 | 0.252 | 0.573 | 0.221 | 1.486 | ||||
| ≥ 500 | 0.669 | 0.848 | 0.398 | 1.806 | ||||
| Time last chemotherapy | ||||||||
| In the last month | - | - | - | - | ||||
| In the last 3 months | 0.662 | 1.145 | 0.623 | 2.104 | ||||
| >3 months before COVID-19 | 0.357 | 0.700 | 0.328 | 1.495 | ||||
| Chemotherapy lines before COVID-19 | ||||||||
| 1 | - | - | - | - | ||||
| 2 | 0.521 | 1.247 | 0.635 | 2.447 | ||||
| 3 | 0.147 | 1.702 | 0.830 | 3.487 | ||||
| 4 | 0.234 | 1.627 | 0.730 | 3.625 | ||||
| >4 | 0.174 | 1.836 | 0.764 | 4.415 | ||||
| SARS-CoV-2 | ||||||||
| α mutation (Alpha) | - | - | - | - | ||||
| β mutation (Beta) | 0.791 | 1.274 | 0.212 | 7.669 | ||||
| Wild type | 0.608 | 1.536 | 0.297 | 7.935 | ||||
| Not tested/Unknown | 0.420 | 1.791 | 0.435 | 7.375 | ||||
| Vaccine doses before COVID-19 | ||||||||
| No vaccination | - | - | - | - | ||||
| One dose | 0.766 | 0.807 | 0.196 | 3.323 | ||||
| Two doses | 0.692 | 0.841 | 0.358 | 1.976 | ||||
| Three doses | 0.968 | 0.000 | 0.000 | . | ||||
| Time last vaccination to COVID-19 | ||||||||
| ≤14 days before COVID-19 | - | - | - | - | ||||
| >14 days before COVID-19 | 0.441 | 2.176 | 0.301 | 15.713 | ||||
| COVID-19 treatment | ||||||||
| No treatment | - | - | - | - | ||||
| Antivirals +/- corticosteroids +/- plasma | 0.312 | 2.014 | 0.519 | 7.818 | ||||
| Monoclonal antibodies +/- corticosteroids +/- plasma | 0.282 | 3.494 | 0.357 | 34.211 | ||||
| Antivirals + monoclonal antibodies +/- corticosteroids +/- plasma | 0.665 | 0.672 | 0.111 | 4.060 | ||||
| Corticosteroids | 0.309 | 2.032 | 0.519 | 7.960 | ||||
| Plasma +/- corticosteroids | 0.969 | 0.000 | 0.000 | . | ||||
| Unknown | 0.466 | 1.549 | 0.477 | 5.027 | ||||